Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciforadenant - Corvus Pharmaceuticals

Next Previous
Drug Profile

Ciforadenant - Corvus Pharmaceuticals

Alternative Names: CPI-444; V 81444

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer Corvus Pharmaceuticals; Genentech; M. D. Anderson Cancer Center; Vernalis
  • Class Amines; Antineoplastics; Antiparkinsonians; Behavioural disorder therapies; Furans; Pyridines; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal cell carcinoma
  • Phase I/II Non-small cell lung cancer
  • No development reported Attention-deficit hyperactivity disorder; Cancer; Multiple myeloma; Parkinson's disease; Solid tumours

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in USA (PO)
  • 28 Jan 2026 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Combination therapy) in USA (PO)
  • 28 Jan 2026 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Combination therapy, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top